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Abstract
AIM: To analyze, retrospectively in a population-
based study, the management and survival of patients 
with recurrent rectal cancer initially treated with a 
macroscopically radical resection obtained with total 
mesorectal excision (TME).
METHODS: A l l rec ta l ca rc inomas d iagnosed 
during 1998 to 2000 and initially treated with a 
macroscopically radical resection (632 patients) 
were selected from the Amsterdam Cancer Registry. 
For patients with recurrent disease, information on 
treatment of the recurrence was collected from the 
medical records.
RESULTS: Local recurrence with or without clinically 
apparent distant dissemination occurred in 62 patients 
(10%). Thirty-two patients had an isolated local 
recurrence. Ten of these 32 patients (31%) underwent 
radical re-resection and experienced the highest 
survival (three quarters survived for at least 3 years). 
Eight patients (25%) underwent non-radical surgery 
(median survival 24 mo), seven patients (22%) were 
treated with radio- and/or chemotherapy without 
surgery (median survival 15 mo) and seven patients 
(22%) only received best supportive care (median 
survival 5 mo). Distant dissemination occurred in 124 
patients (20%) of whom 30 patients also had a local 
recurrence. The majority (54%) of these patients 
were treated with radio- and/or chemotherapy without 
surgery (median survival 15 mo). Twenty-seven 
percent of these patients only received best supportive 
care (median survival 6 mo), while 16% underwent 
surgery for their recurrence. Survival was best in the 
latter group (median survival 32 mo).
CONCLUSION: Although treatment options and 
survival are limited in case of recurrent rectal cancer 
after radical local resection obtained with TME, patients 
can benefit from additional treatment, especially if a 
radical resection is feasible.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
Colorectal cancer is the second most common cancer in 
the Western world and approximately one third of  these 
tumours are located in the rectum or rectosigmoid[1]. 
Annually, over 3000 patients are registered with a 
newly diagnosed rectal or rectosigmoid carcinoma in 
the Netherlands[2,3]. In these patients, locally recurrent 
disease is a major concern and is often accompanied 
with intractable pain and severely disabling complications 
which are difficult to treat[4-6]. It has a tremendous impact 
on quality of  life[7] and frequently induces an awful last 
period of  a patient's life. Therefore, the focus in rectal 
cancer research has been on the prevention of  locally 
recurrent disease, which resulted in the introduction of  
preoperative radiotherapy and total mesorectal excision 
(TME)[8-12].
There are many repor ts on the treatment of  
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recurrent rectal cancer[4,6,13-16]. However, these reports 
present mainly results from randomised clinical trials or 
specialised institutes, which are known to be biased[17]. 
There are only a few population-based reports on the 
treatment of  locally recurrent rectal cancer disease[13,18], 
although they are probably the best reflection of  daily 
practice.
I n 1 9 9 6 , T M E wa s i n t r o d u c e d i n G r e a t e r 
Amsterdam, the region of  the Comprehensive Cancer 
Centre Amsterdam (CCCA). Its introduction was 
facilitated by the CCCA. Surgeons were supervised by 
teacher-surgeons in order to qualify as TME-surgeon 
and a documentation project was started to investigate 
the influence of  TME-surgery on the incidence of  local 
recurrences and survival[19]. From 1998 on, all patients 
in Greater Amsterdam are treated with TME in case of  
rectal resection.
The aim of  the present study was to analyze, 
retrospectively in a population-based setting, the 
management and survival of  patients with recurrent 
rectal cancer, initially treated with macroscopically radical 
local resection obtained with TME.
MATERIALS AND METHODS
Cancer registry data
All primary rectal carcinomas (rectosigmoid excluded) 
diagnosed in patients with residence in Greater 
Amsterdam, the region of  the CCCA, between January 
1, 1998 and December 31, 2000, and who underwent 
a macroscopically radical resection obtained with 
TME in the absence of  distant dissemination, were 
selected from the Amsterdam Cancer Registry of  the 
CCCA. The Amsterdam Cancer Registry is a regional, 
population-based cancer registry with complete regional 
coverage. Non-epithelial cancers, carcinoids and cases 
with preceding invasive cancers were excluded. The 
population of  the region amounted to 2.8 million 
inhabitants on December 31, 2000, approximately 17% 
of  the total population of  the Netherlands.
The information for the cancer registry is routinely 
extracted from detailed hospital and outpatient clinic 
records by registration clerks. Apart from demographic 
data, data are collected on morphological classification, 
stage of  the tumour and primary treatment of  the 
patients. The TNM system for classif icat ion of  
malignant tumours is prospectively registered to classify 
all rectal carcinomas. Stage grouping in this study was 
performed according to the 6th edition of  the TNM-
classification[20], based on the available information after 
surgery (pTNM).
Of  the selected cases, a supplementary data set 
was extracted from the medical records. This data set 
included the occurrence and the date of  local recurrence 
or distant dissemination. Local recurrence was defined 
as cancer recurrence within the lower pelvis. Additional 
treatment of  recurrence, the presence of  microscopic 
or macroscopic residual disease after salvage surgery for 
recurrent disease, the date of  salvage surgery and the 
cause of  death were also collected. Cases were generally 
followed for five, but at least three years after the date of  
initial surgery.
Vital status
The vital status was updated by active follow-up in 
the hospitals, by linking files with deceased persons 
to the cancer registry and by linkage to the electronic 
death registry of  the Central Office for Genealogy 
in September, 2003 and February, 2005, as described 
earlier[21]. Completeness of  follow-up of  the vital status 
is estimated to be over 99.5%.
Statistical analysis
P < 0.05 was considered statistically significant. All 
statistical analyses were performed using a two-sided 5% 
level of  significance.
Survival probabilities were estimated using the 
Kaplan-Meier method[22]. Multivariate analyses using the 
Cox proportional-hazard method were performed to 
calculate the hazard ratio (HR) for death after recurrent 
disease[23]. Cox regression and Kaplan-Meier survival 
curves were calculated with STATA (Stata Corporation, 
College Station, TX, USA).
RESULTS
Initial treatment and incidence of local recurrence
A total of  632 patients diagnosed with primary rectal 
carcinoma in the absence of  clinically manifest distant 
dissemination between 1998 and 2000 underwent a 
macroscopically radical local resection obtained with 
TME. Characteristics of  the initial treatment of  the 
primary tumour in these patients are given in Table 1. 
Local recurrence within five years after diagnosis 
occurred in 62 patients (10%), including 30 cases with 
distant dissemination (6%). Of  these 30 patients, 24 
patients had synchronous local and distant recurrence, 
while 6 patients developed distant dissemination after 
the local recurrence.
Treatment of local recurrence
There were 32 out of  62 patients (52%) without signs 
Table 1  Initially applied radiotherapy in surgically treated, 
primary rectal carcinoma patients according to pTNM-stage in 
Greater Amsterdam, the Netherlands, 1998 to 2000
Stage of 
disease
Number of cases 
(% of total)
Radiotherapy, number of patients (%)
No RT Postoperative 
RT
Preoperative 
RT
Ⅰ 209 (33) 115 (55) 1 (0) 93 (45)
ⅡA 180 (28)   72 (40) 26 (14) 82 (46)
ⅡB 20 (3)     2 (10)   6 (30) 12 (60)
ⅢA 32 (5)     8 (25) 11 (34) 13 (41)
ⅢB 113 (18)   26 (23) 32 (28) 55 (49)
ⅢC   72 (11)   13 (18) 23 (32) 36 (50)
Unknown   6 (1)     2 (33) -   4 (67)
Total          632 238 (38) 99 (16)      295 (47)
RT: Radiotherapy.
of  distant dissemination at the time of  diagnosis of  
recurrent disease. Median survival after recurrence 
in the absence of  distant dissemination was 25 mo. 
Ten of  these 32 patients underwent a microscopically 
radical resection of  their recurrence (Table 2). As 
is depicted in Figure 1, radical surgery resulted in a 
significantly better survival than non-radical surgery, 
radio- and/or chemotherapy without surgery or best 
supportive care (log-rank test radical surgery vs other 
treatments: P < 0.001). About three quarters of  the 
patients who underwent a radical resection survived for 
at least three years. Median survival after non-radical 
surgery (8 patients) was 24 mo, 7 mo after radio- and/or 
chemotherapy without surgery (7 patients) and was 5 mo 
in case of  best supportive care only (7 patients).
In 30 patients (48%), distant dissemination was 
present at the time of  diagnosis of  local recurrent 
disease. Median survival after local recurrence in the 
presence of  distant dissemination was 10 mo. None of  
these patients underwent curative surgery, two patients 
underwent non-radical surgical resection, 14 patients 
were treated with radio- and/or chemotherapy without 
surgery (median survival 14 mo) and 14 patients received 
best supportive care only (median survival 9 mo).
Prognostic factors for survival after recurrence
Several factors were analysed to identify prognostic 
factors for improved survival after local recurrence. The 
results of  the multivariate analysis are shown in Table 3. 
Surgery for recurrent disease (radical and non-radical) 
was a prognostic factor for improved survival, while 
radiotherapy applied during the initial treatment did not 
influence survival after local recurrence (Figure 2).
Distant dissemination
Distant dissemination within five years after diagnosis 
occurred in 124 patients (20%). The majority of  patients 
(54%) with distant dissemination were treated with 
radio- and/or chemotherapy (Table 4). The median 
survival after distant dissemination was 15 mo.
Twenty patients (16%) underwent surgery for 
their recurrence, including liver resections in eight 
patients, lung resections in five patients, and other 
surgical procedures in seven patients. Median survival 
after surgery was 32 mo, while median survival after 
radiotherapy and/or chemotherapy without surgery was 
15 mo and 6 mo if  best supportive care was applied 
(Figure 3). Patients with distant dissemination who were 
treated surgically experienced the highest survival (log-
rank test surgery vs other treatments: P < 0.001).
DISCUSSION
This is the first population-based study concerning 
Table 2  Secondary treatment of local recurrence (in the absence of distant dissemination) according to treatment with radiotherapy 
and stage at initial diagnosis (after a macroscopically radical resection obtained with TME)
Secondary treatment Stage and treatment with radiotherapy at initial diagnosis
Stage Ⅰ Stage Ⅱ Stage Ⅲ Total
 n (%)No RT Post RT Pre RT No RT Post RT Pre RT No RT Post RT Pre RT
Radical surgery1 (± radiotherapy and/or 
chemotherapy)
3 - 1 3 - 1 1 - 1 10 (3)
Non-radical surgery1 (± radiotherapy and/or 
chemotherapy) 
- - - 2 1 2 - 3 -   8 (2)
Radiotherapy and/orchemotherapy without surgery 2 - - 1 1 - 1 2 -   7 (2)
Best supportive care 1 - - - 1 3 1 - 1   7 (2)
Total 6 - 1 6 3 6 3 5 2 32
1Radical surgery was defined as surgery without microscopically residual disease; all other surgery cases were classified as non-radical. No RT: No 
radiotherapy; Post RT: Postoperative radiotherapy; Pre RT: Preoperative radiotherapy.
Table 3  Multivariate analysis of potentially prognostic factors 
for improved survival after treatment of patients with a 
locally recurrent rectal carcinoma in Greater Amsterdam (cases 
with distant dissemination and/or macroscopic residual disease 
at time of initial treatment are excluded)
Parameter Number of cases HR (95% CI)
Sex
   Male (reference) vs female 33/29 1.9 (0.9-3.7)
Radiotherapy at initial treatment
   No radiotherapy 23 1.0
   Preoperative radiotherapy 23 1.2 (0.6-2.5)
   Postoperative radiotherapy 16 0.9 (0.4-1.8)
Distant dissemination at time of local recurrence
   Absent (reference) vs present 32/30 0.8 (0.4-1.6)
Surgical treatment of locally recurrent disease
   No surgery 42 1.0
   Radical surgery 10 0.1 (0.0-0.3)
   Non-radical surgery 10 0.5 (0.2-1.3)
HR > 1: Worse prognosis; HR < 1: Better prognosis.
1Synchronous with distant metastasis or prior to distant metastasis.
Treatment No local  
recurrence
Local        
recurrence1 Total
n % n % n %
Surgery1 (± radiotherapy 
and/or chemotherapy)
18 19   2   7 20 16
Radiotherapy and/or 
chemotherapy
54 57 13 43 67 54
Other   1   1   2   7   3   2
Best supportive care 21 22 13 43 34 27
Total 94 30    124
Table 4  Treatment of distant dissemination in patients 
initially treated with a macroscopically radical local resection 
obtained with TME in the absence of distant metastasis
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recurrent rectal cancer treatment after the introduction 
of  TME. All patients in this study were initial ly 
d i agnosed be tween 1998 and 2000 in Grea te r 
Amsterdam and treated by macroscopically radical 
local resection obtained with TME. A local recurrence 
occurred in 62 of  the 632 patients (10%), while distant 
dissemination was found in 124 patients (20%).
Treatment of patients with isolated recurrent disease
Of  the 32 patients with an isolated local recurrence, 
31% were treated by a radical resection. These patients 
experienced a significantly better survival compared 
to patients who underwent a non-radical resection for 
their recurrence. As has been shown previously, radical 
resection of  locally recurrent disease can achieve long-
term survival[4,13-15,24] and should, therefore, be aimed 
at, even if  extended resection (e.g. abdominosacral 
resection or exenteration)[16,25,26] or flap-reconstruction[27] 
is required.
Sur vival in patients treated with non-radical 
surgery and patients treated with radiotherapy and/or 
chemotherapy without surgery was comparable, but 
was significantly worse in patients not treated with 
surgery, radiotherapy or chemotherapy. Although no 
information concerning the extent of  recurrent disease 
was available in this study, treatment has probably been 
more aggressive in case of  limited disease and, therefore, 
selection bias may have played an important role in the 
outcome of  the various treatment modalities.
Treatment of patients with distant dissemination
The median survival after distant dissemination was 
15 mo for patients diagnosed between 1998 to 2000. 
In a previous study, we have described that patients 
diagnosed in 1988 between 1991 in Greater Amsterdam 
only survived 9 mo after distant dissemination (log-rank 
test: P = 0.004)[19]. The majority of  patients diagnosed 
between 1998-2000 (54%) with distant dissemination 
were treated with radiotherapy and/or chemotherapy 
without surgery, while 16% were treated with surgical 
resection and 27% received only best supportive care. 
Survival was significantly better in the group of  patients 
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Figure 3  Crude survival after distant dissemination in rectal cancer patients 
initially treated with a macroscopically radical local resection obtained with TME 
in Greater Amsterdam according to treatment for distant dissemination.
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Figure 1  Crude survival after isolated local recurrence in rectal cancer patients 
initially treated with a macroscopically radical local resection obtained with TME 
in Greater Amsterdam according to treatment for recurrence. Radical surgery 
is defined as surgery without macroscopically or microscopically residual 
disease. Non-radical surgery is defined as surgery with macroscopically or 
microscopically residual disease.
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Figure 2  Crude survival after isolated local recurrence in rectal cancer patients 
initially treated with a macroscopically radical local resection obtained with TME 
in Greater Amsterdam according to radiotherapeutic treatment of the primary 
tumour.
treated with surgery compared to other groups. This 
is probably due to the limited spread of  disease in 
these patients (selection bias). As no treatment data 
were available for the patients diagnosed between 1988 
to 1991 in Greater Amsterdam, it is unclear which 
treatment modality has contributed to the increase in the 
median survival.
CONCLUSION
In this population-based study, treatment options and 
survival were limited in patients with recurrent rectal 
cancer after macroscopically radical local resection 
obtained with TME. Approximately one third of  the 
patients only received best supportive care with a 
subsequent poor survival. On the other hand, in one 
third of  the patients with an isolated local recurrence, 
radical resection was feasible with a favourable survival. 
We conclude that a locally recurrent rectal cancer 
without distant dissemination does not automatically lead 
to a hopeless situation[28]. However, survival after local 
recurrence in combination with distant dissemination 
remains extremely poor.
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Background
Colorectal cancer is a common cancer in the Western world and rectal cancer 
has been subject to significant treatment changes over the last decade. Despite 
this change, recurrent rectal cancer treatment remains a frustrating and ongoing 
process.
Research frontiers
In the recent decade, the main changes in rectal cancer treatment have 
been the application of preoperative radiotherapy and the introduction of total 
mesorectal excision (TME) which led to a significant decrease in local recurrence 
percentages. In the current article, the influence the introduction of TME on 
recurrent rectal cancer treatment is evaluated in a population based cohort.
Applications
The current results show that recurrent rectal cancer treatment is in some cases 
worthwhile, especially if a radical resection is feasible. However, avoiding a 
local recurrence remains an important aspect in future rectal cancer treatment.
Terminology
TME is a surgical technique initiated by B. Heald during which the entire 
mesorectum is excised using the so-called “holy” plane. This provides the 
opportunity to remove the entire rectum with possibly infiltrated lymph nodes.
Peer review
This is an interesting study which was well organized. It demonstrated that 
although treatment options and survival are limited in case of recurrent rectal 
cancer after radical local resection obtained with TME, patients can benefit from 
additional treatment, especially if a radical resection is feasible.
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